DexCom Inc. ($DXCM) Stock Forecast: Up 6.0% Today

What is DexCom Inc.?

DexCom, Inc. (DXCM) is a medical device company specializing in continuous glucose monitoring systems. Today, the stock experienced a strong bullish movement in the market.

Why is DexCom Inc. going up?

DXCM stock is up 6.0% on May 1, 2026 13:51

• DexCom (DXCM) reported impressive Q1 2026 financial results, with revenue exceeding expectations and driven by strong demand for its CGM products, particularly the G7 15-day system.
• The company's significant margin expansion and raised profitability guidance showcased strong operational efficiencies and market reception, contributing to the bullish movement in the stock.
• Despite concerns about sustained margin expansion and potential revenue growth deceleration, DexCom's strategic initiatives and positive outlook for the year contributed to investor confidence and the bullish market movement.

DXCM Price Chart

DXCM Technical Analysis

DXCM News

BTIG Remains Bullish on DexCom, Inc. (DXCM)

BTIG has reiterated a Buy rating on DexCom, Inc. (DXCM) despite cutting its price target to $80 from $85 due to updated models reflecting CMS announcements on new technology add-on payments. DexCom, a medical device company specializing in continuous glucose monitoring systems, is set to release its Q1 2026 financial results and has provided positive FY26 guidance. The article highlights DXCM as a strong medical device stock while also pointing to potentially higher-return AI stock opportunities.

https://www.insidermonkey.com/blog/btig-remains-bullish-on-dexcom-inc-dxcm-1751258/

DexCom (DXCM) Q1 2026 Earnings Transcript

DexCom (DXCM) reported strong Q1 2026 financial results, with worldwide revenue reaching $1.19 billion, reflecting 15% reported growth and 12% organic growth, driven by broad CGM demand and new product launches, including the G7 15-day system. The company reaffirmed its 2026 revenue guidance while increasing its non-GAAP operating profit and adjusted EBITDA margin outlooks, crediting operational efficiencies and strong market reception. DexCom also announced significant commercial coverage expansion for the type 2 non-insulin diabetes segment and anticipates the readout of a key randomized control trial at the ADA's 2026 Scientific Sessions, reinforcing its commitment to expanding access and product innovation.

https://www.fool.com/earnings/call-transcripts/2026/04/30/dexcom-dxcm-q1-2026-earnings-transcript/

DexCom Q1 2026 slides: margin expansion accelerates, guidance raised

DexCom (NASDAQ:DXCM) exceeded Q1 2026 expectations with $1.19 billion in revenue, driven by continuous glucose monitoring product demand and strategic initiatives like the G7 15 Day system. The company demonstrated significant margin expansion, with adjusted EBITDA margin reaching 30.6%, and subsequently raised its full-year 2026 profitability guidance while maintaining its revenue outlook. Despite strong performance, the stock trades near its 52-week low, indicating investor caution regarding sustained margin expansion and potential deceleration in revenue growth amidst competitive and geopolitical challenges.

https://www.investing.com/news/company-news/dexcom-q1-2026-slides-margin-expansion-accelerates-guidance-raised-93CH-4651677

DexCom Q1 2026 Earnings Call Transcript

DexCom reported a 15% increase in first-quarter revenue, reaching $1.19 billion, driven by strong demand for its CGM products, especially with the launch of the G7 15-day system and expanded insurance coverage. The company secured a significant reimbursement win with Prime Therapeutics for the commercial type 2 non-insulin population, set to cover over 7 million lives by year-end. DexCom maintained its full-year revenue guidance while raising its operating profit and adjusted EBITDA margin guidance, demonstrating strong operational execution and cost control.

https://www.benzinga.com/insights/news/26/04/52201217/dexcom-q1-2026-earnings-call-transcript

Stryker beats The Street despite Q1 cyberattack, sticks with guidance

Stryker reported first-quarter results that exceeded Wall Street expectations and maintained its full-year guidance, despite a cyberattack in early March that disrupted operations. The company's Q1 EPS was $2.60, 38¢ ahead of analyst estimates, with sales of $6.020 billion. Stryker also announced organizational changes and an agreement to acquire Amplitude Vascular Systems.

https://www.massdevice.com/stryker-beats-the-street-despite-q1-cyberattack-sticks-with-guidance/

Trending Today

GoPro Inc. ($GPRO) Stock Forecast: Down 16.5% Today

Xerox Corporation ($XRX) Stock Forecast: Down 15.5% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 8.3% Today

GlobalFoundries Inc. ($GFS) Stock Forecast: Up 5.6% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Up 5.4% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 6.4% Today

Plug Power Inc. ($PLUG) Stock Forecast: Up 6.6% Today

Patterson-UTI Energy Inc. ($PTEN) Stock Forecast: Up 5.2% Today

Leidos Holdings Inc. ($LDOS) Stock Forecast: Down 5.5% Today

KKR & Co. Inc. Class A ($KKR) Stock Forecast: Down 5.4% Today

DexCom Inc. Price History

03.01.2026 - DXCM Stock was down 1.8%

• The decline in DXCM stock value could be linked to investors selling off their shares to secure profits following a period of substantial growth and optimistic forecasts for 2026.
• The recent change in leadership, marked by the appointment of new CEO, Jake Leach, may have prompted some uncertainty among investors, leading to selling pressure.
• Despite Peterson Wealth Services increasing their ownership in DXCM, the mixed activity among company insiders and the general market sentiment may have influenced the downward trend.
• The upcoming earnings reports from Diodes (DIOD) and Universal Technical Institute (UTI) are potential factors impacting investor confidence in the healthcare sector, contributing to the negative pressure on DXCM stock.

12.00.2026 - DXCM Stock was up 5.3%

• DexCom's stock had a notable bullish trend, propelled by robust preliminary Q4 results that surpassed revenue expectations and demonstrated significant growth in both domestic and international markets.
• The introduction of DexCom's G7 15-Day sensor and the FDA approval for Smart Basal technology have been key factors in fostering positive market sentiment, revealing a high demand for the company's advanced products.
• Analysts at Morgan Stanley maintained an Overweight rating for DexCom, pointing to the strong Q4 results and the appointment of a new CEO as favorable catalysts for the company's future growth.
• While there are varied analyst opinions on DexCom's valuation, the general market sentiment remains optimistic, with investors looking forward to the company's sustained revenue growth, enhanced margins, and expansion strategies for 2026.

22.00.2026 - DXCM Stock was up 4.4%

• Despite challenges like a recent Class 1 recall for some G7 receivers, Dexcom announced an impressive Q3 2024 revenue growth of 22% year-over-year, amounting to $1.2 billion. This growth was fueled by expanding its customer base and launching new products such as the Stelo for non-insulin users.
• Analysts have a positive consensus on DXCM, rating it as a "Strong Buy" with an average price target of $85.00, indicating a potential upside of 22.6%. This positive sentiment stems from the company's strong performance in the healthcare industry and its ability to capture the growing market of diabetes patients embracing CGM technology.
• The rise in DXCM's stock price today is attributed to its strong financial performance, favorable analyst ratings, and the overall growth opportunities in the healthcare sector, particularly in patient monitoring.
• Institutional ownership of DXCM remains high at 97.75%, despite Fisher Funds Management LTD selling a portion of its stake, showcasing ongoing confidence in the company's future prospects and market position.

01.04.2026 - DXCM Stock was up 6.0%

• DexCom (DXCM) reported impressive Q1 2026 financial results, with revenue exceeding expectations and driven by strong demand for its CGM products, particularly the G7 15-day system.
• The company's significant margin expansion and raised profitability guidance showcased strong operational efficiencies and market reception, contributing to the bullish movement in the stock.
• Despite concerns about sustained margin expansion and potential revenue growth deceleration, DexCom's strategic initiatives and positive outlook for the year contributed to investor confidence and the bullish market movement.

27.02.2026 - DXCM Stock was down 6.2%

• The amendment filed by a major institutional investor, stating it no longer beneficially owns any shares of DXCM, might have raised concerns among investors, leading to a sell-off.
• DXCM underperforming compared to its competitors and the broader market could have contributed to the bearish movement, as investors may have shifted their focus to other more promising opportunities.
• Despite Dexcom's impressive Q4 earnings and institutional buying interest, the overall negative sentiment in the market, coupled with concerns about the company's future growth prospects amidst competition and regulatory hurdles, likely weighed down on the stock price.

27.02.2026 - DXCM Stock was down 5.9%

• DXCM's stock price saw a considerable decrease in line with major indices like the S&P 500 and Dow Jones Industrial Average. This decline was influenced by rising uncertainties related to the U.S.-Iran conflict and impending policy decisions by the Trump administration.
• Despite DXCM exhibiting robust Year-over-Year EBITDA Growth of 52.52% and being deemed significantly undervalued, some investors may have exercised caution due to certain warning signals identified in the analysis.
• The recent disclosure by Vanguard Group, revealing no holdings of DXCM common stock subsequent to an internal reshuffling, may have further dampened investor sentiment towards the company.
• DXCM's underperformance in comparison to its competitors on Thursday and the conclusion of a two-day positive streak could have also played a role in the stock's downward trajectory, particularly amid the widespread market declines observed.

05.02.2026 - DXCM Stock was down 1.7%

• DexCom's stock witnessed a downturn despite surpassing analyst projections with its quarterly earnings. This drop may be linked to significant sell-offs made by Fisher Asset Management LLC.
• While institutional holdings from leading firms like Vanguard, MFS, and Picton Mahoney Asset Management saw an increase, it was insufficient to counterbalance the impact of Fisher Asset Management's divestment, leading to a negative trend in the stock price.
• Analysts have maintained a "Moderate Buy" consensus on DexCom, with an average target price of $85.18. This suggests continued faith in the company's prospects, even amidst ongoing market fluctuations influenced by institutional trading.

29.03.2026 - DXCM Stock was down 5.2%

• The launch of Dexcom Academy, a new educational platform for healthcare professionals, while a positive development for the company, may not have been sufficient to offset the bearish sentiment in the market.
• Competitor news from Tandem Diabetes Care receiving FDA clearance for its automated insulin delivery technology for pregnancy in Type 1 Diabetes could have potentially shifted investor focus away from Dexcom.
• Overall, the bearish movement in Dexcom's stock today could be attributed to a combination of market factors, including competition in the diabetes device market and general market sentiment impacting the healthcare sector.

29.03.2026 - DXCM Stock was down 5.3%

• Today's downward movement in DexCom's stock could be due to some investors selling off shares to realize profits after a period of price appreciation.
• Heightened volatility in DXCM's stock price leading up to the Q1 earnings announcement might be driven by market expectations.
• Despite positive industry sentiments, external factors such as market conditions or concerns about profit margins could have contributed to the bearish trend observed in DXCM today.

13.01.2026 - DXCM Stock was up 8.3%

• DexCom's stock price saw an 8.4% increase following the company's surpassing of Q4 earnings and revenue expectations, demonstrating robust financial performance and market confidence.
• Analysts have revised upwards their price objectives for DXCM, with targets raised to $85.05 by Mizuho and $90.00 by BTIG, indicating positive sentiment and potential for further advancement.
• The successful launch of innovative products like the DexCom G7 15-day system and DexCom Smart Basal, alongside opportunities for expansion into international markets, have contributed to the positive market trend.
• Although encountering short-term challenges like trading below moving averages and a high P/E ratio, DexCom's strong financial position, optimistic market growth outlook, and upcoming catalysts point towards a bright future for the company.

13.01.2026 - DXCM Stock was up 7.4%

• Despite DexCom's strong financial performance, including beating Q4 earnings and revenue estimates, the stock experienced a slight fall in after-hours trading. This could be due to profit-taking by investors after a recent surge in the stock price.
• The anticipation of expanded Medicare coverage for CGMs for Type 2 diabetes patients is a positive development for DexCom, indicating potential growth opportunities in a new market segment.
• The company's 2026 revenue forecast falling slightly below analysts' expectations may have contributed to some investor uncertainty, leading to the mixed market movement despite the positive earnings beat.
• Overall, the bullish movement in DexCom's stock today could be attributed to the company's strong financial performance, anticipation of expanded market opportunities, and positive analyst reactions, despite some lingering concerns about revenue forecasts.

13.01.2026 - DXCM Stock was up 5.2%

• The positive movement in DXCM stock today is driven by the impressive Q4 performance and optimistic outlook shared during the earnings call.
• Mizuho's increase in price targets and "Buy" ratings maintained by Wells Fargo and Stifel reflect favorable analyst sentiment and confidence in the company's future growth potential.
• Despite some immediate challenges like trading below moving averages and a high P/E ratio, investor confidence remains high due to DXCM's innovative products like the DexCom G7 15-day system and DexCom Smart Basal, as well as substantial international expansion opportunities.
• Anticipated catalysts in 2026, such as potential Medicare coverage and new product launches, contribute to the positive market sentiment surrounding DXCM, positioning it as a top choice in the diabetes sector and potentially undervalued per InvestingPro's Fair Value assessment.